KIMS Q2 FY27 Results & Earnings Analysis
Sentiment: Good (Confidence: high)
Earnings Summary
KIMS Hospitals reported strong Q2 FY27 results with consolidated revenue of INR1,363 crores (+41.3% YoY, +14% QoQ), EBITDA of INR279 crores (+34% YoY, +16.3% QoQ), and PAT of INR76 crores (vs INR37 crores QoQ, INR72 crores YoY). EBITDA margin at 20.5% represents a 120 bps YoY decline primarily due to new hospital fixed costs and one-time doubtful debt provisions but management guided Q2 as the bottom with upward trajectory expected. Volume growth was strong with IP volumes +27% YoY and OP volumes +23.3% YoY. The company completed multiple acquisitions (KIMS Trust Hospital Kakinada 51% for INR80 cr, Ushahkal Abhinav Sangli 6% for INR15 cr) and O&M agreements (Arete Gachibowli 300 beds, Westfort Thrissur 300 beds). Kondapur new hospital ramped exceptionally with 70% revenue growth in 3 months at 70-75% occupancy. Capex of INR650 crores spent in H1 with ~INR1,100 crores planned over next 18 months. Net debt at INR2,150 crores (1.9x EBITDA) post QIP. Key risks include regulatory pricing changes (trade margin rationalization on anti-cancer drugs, Kerala private hospital regulation) and insurance empanelment delays, though these appear manageable.
Management Tone
- Prepared Remarks: Good — Prepared remarks highlighted strong operational and financial growth, multiple new acquisitions and O&M agreements, capacity expansions, and a confident festive greeting with expectations to do even better in coming year .
- Q&A Session: Good — Management addressed margin trajectory confidently, quantified onco drag and doubtful debt provisions, provided specific occupancy and ramp-up timelines, and clarified capex/debt details with specific numbers .
Revenue Growth Drivers
- IP volume growth of 27% YoY and 12.7% QoQ
- OP volume growth of 23.3% YoY and 11% QoQ
- ARPOB expansion of 14.9% YoY and 2.3% QoQ
Growth vs Margin Focus
Management explicitly targeting growth through new hospital ramp-ups, acquisitions, and O&M expansion while expecting margin recovery as new units stabilize; stated Q2 is bottom for margins with upward trajectory expected, targeting 30% margins at Telangana and 20%+ consolidated . Company is investi
About Krishna Institute of Medical Sciences Limited
Krishna Institute of Medical Sciences Limited (KIMS) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.